TriangleCC-99282 + Rituximab (NCT06209619)
CC-99282 + Rituximab trial for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NCT06209619). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for B cell non-Hodgkin lymphoma in adults whose response to CAR T cell therapy was not optimal.
The idea: add a drug combination early after CAR T. Patients receive rituximab by vein and golcadomide, also called CC-99282, by mouth, in 28 day cycles for up to six cycles. Rituximab targets CD20, a protein on B cells.
This phase 1 study looks for the best dose and the side effects, and plans 18 patients. At Ohio State University Comprehensive Cancer Center, Nathan Denlinger leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.